. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Am J Ophthalmol. 2012 Dec 6;155(4):688–696.e2. doi: 10.1016/j.ajo.2012.10.003

TABLE 4.

Beneficiaries With Exudative Age-Related Macular Degeneration Receiving Bevacizumab, Ranibizumab, or Pegaptanib Within 1 Year of First Diagnosis Conditional on Receipt of Anti-VEGF Therapy, by Proximity to a Major Teaching Hospital (%)

Year of First Diagnosis	Bevacizumab			Ranibizumab			Pegaptanib
Year of First Diagnosis	MTH County	MTH HRR	Other HRR	MTH County	MTH HRR	Other HRR	MTH County	MTH HRR	Other HRR
2005	39.1	45.9	38.5	10.9	17.3	13.3	68.8	62.2^a	73.8
2006	60.8	66.0	61.1	42.7	43.8	43.1	22.0	16.0^a	22.3
2007	69.7	70.1	65.2	41.6	41.8	46.5	1.2	2.2	1.7
2008	72.9	78.3^a	72.6	39.1	33.1	36.7	0.4	0.9	0.3
2009	70.3	73.1	73.4	41.4	38.8	39.0	0.9	0.4	1.3

HRR = Hospital Referral Region; MTH = major teaching hospital; VEGF = vascular endothelial growth factor.

Area compared with Other HRR (t test); P < .01.

Area compared with Other HRR (t test); P < .05.